Research and Markets: China Executive Summary of the Chinese Hospital Drug Utilization Volume 2nd Edition 2009

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/de26ab/china_executive_su) has
announced the addition of the "China Executive Summary of the Chinese Hospital
Drug Utilization Volume 2nd Edition 2009" report to their offering.

The total Chinese pharmaceutical market had reached RMB 828.36 billion (US$
120.84 billion, at an exchange rate of US $1 = RMB 6.83) with an annual growth
rate (AGR) of 26.50% in 2008. The growth rate, as well as the absolute size of
the rapidly-expanding Chinese pharmaceutical market, is no doubt astonishing.
The categorization of the Chinese pharmaceutical market as one of the "emerging
pharmaceutical market" may need to be reconsidered. Even though the current
Chinese pharmaceutical market is still mainly a generic market, many of the
innovative drugs have been rapidly up-taken by large Chinese hospitals in major
cities. Some of the highly-priced oncology drugs, for example, erlotinib and
trastuzumab, have made into the list of top 20 cancer drugs (by sales) in the
last few years.

Many pharmaceutical companies have realized that just locking their eyes at the
"mature" pharmaceutical markets (US, Europe and Japan) is no longer enough to
sustain growth, especially for the future growth.

This Second Edition of the China Pharma Executive Summary provides hospital drug
utilization data for 14 key therapeutic areas, including asthma, cancer, liver
diseases, diabetes, hypertension, depression, allergy, dementia, benign prostate
hyperplasia (BPH), ophthalmology, hyperlipoidemia, rheumatoid arthritis,
dermatosis, and blood products, etc.

Key contents include:

* 2008 annual drug sales in the Chinese hospital market for each therapeutic
area*.
* Sales and market shares of top 20 manufacturers in each therapeutic area.
* Sales and market shares of top drugs in each therapeutic area.

Annual drug sales in each of the eight therapeutic areas (cancer, blood
diseases, liver diseases, dermatosis, hypertension, diabetes, dementia, and
hyperlipidemics) had passed US $1 billion in 2008. Sales of cancer drugs in the
Chinese hospital market reached US $4.612 billion, followed immediately by blood
products which had US $3.966 billion in 2008. Except skin disease, eye disease,
allergy and BPH, drug sales in all other therapeutic areas had achieved double
digit growth rates in 2008. *: Drug prices are based on the hospital drug
purchase prices in 2008 for all drug utilization data in this report.

Key Topics Covered:

* Methodology
* Overview
* Section 1: China Benign Prostate Hyperplasia (BPH) Drug Market
* Section 2: China Asthma Drug Market
* Section 3: China Depression Drug Market
* Section 4: China Dementia Drug Market
* Section 5: China Cancer Drug Market
* Section 6: The China Allergy Drug Market
* Section 7: China Hypertension Drug Market
* Section 8: Dermatosis Drug Market
* Section 9: China Ophthalmological Drug Market
* Section 10: China Rheumatoid Arthritis (RA) Drug Market
* Section 11: China Diabetes Drug Market
* Section 12: Liver Disease Drug Market
* Section 13: China Blood Product Market
* Section 14: China Hypolipidemics Drug Market
* Tables

For more information visit
http://www.researchandmarkets.com/research/de26ab/china_executive_su

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2009